Bayesian Capital Management’s Guardant Health GH Stock Holding History

Bayesian Capital Management’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,652	Closed	-$762K	–	633
2025 Q2	$762K	Buy	+14,652	New	+$654K	0.12%	219
2024 Q1	–	Sell	-18,300	Closed	-$495K	–	897
2023 Q4	$495K	Sell	18,300 -20,400	-53%	-$535K	0.05%	386
2023 Q3	$1.15M	Buy	+38,700	New	+$1.36M	0.13%	192
2020 Q1	–	Sell	-12,714	Closed	-$993K	–	842
2019 Q4	$993K	Sell	12,714 -18,100	-59%	-$1.3M	0.17%	177
2019 Q3	$1.97M	Buy	30,814 +21,597	+234%	+$1.9M	0.37%	65
2019 Q2	$796K	Buy	9,217 +5,911	+179%	+$451K	0.16%	174
2019 Q1	$254K	Buy	+3,306	New	+$183K	0.05%	422

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayesian Capital Management's GH Position: Q3 2025 in Review

Bayesian Capital Management sold out of Guardant Health (GH) in Q3 2025, closing a stake of 14,652 shares — an estimated $762K sold.

Bayesian Capital Management first reported a position in GH in Q1 2019 and held it in 7 quarters. The position peaked at $1.97M in Q3 2019. 395 funds tracked by Wall St. Rank hold GH as of Q3 2025.

Bayesian Capital Management reported no remaining Guardant Health position as of Q3 2025 after selling out during the quarter.
Bayesian Capital Management sold 14,652 Guardant Health shares in Q3 2025, an estimated $762K.
Bayesian Capital Management first reported a position in Guardant Health in Q1 2019 and held it in 7 quarters.
Bayesian Capital Management's Guardant Health position peaked at $1.97M in Q3 2019.
395 funds tracked by Wall St. Rank held Guardant Health as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.